DK2433637T3 - Anvendelse af quinazolin derivater til neurodegenerative sygedomme - Google Patents
Anvendelse af quinazolin derivater til neurodegenerative sygedomme Download PDFInfo
- Publication number
- DK2433637T3 DK2433637T3 DK10732398.2T DK10732398T DK2433637T3 DK 2433637 T3 DK2433637 T3 DK 2433637T3 DK 10732398 T DK10732398 T DK 10732398T DK 2433637 T3 DK2433637 T3 DK 2433637T3
- Authority
- DK
- Denmark
- Prior art keywords
- aryl
- alkyl
- use according
- compound
- formula
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims description 16
- 230000004770 neurodegeneration Effects 0.000 title description 7
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- -1 amino acid ester Chemical class 0.000 claims description 21
- 208000018737 Parkinson disease Diseases 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 208000012902 Nervous system disease Diseases 0.000 claims description 13
- 208000025966 Neurological disease Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 230000000626 neurodegenerative effect Effects 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229910052727 yttrium Inorganic materials 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000010118 dystonia Diseases 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims description 4
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 208000016620 Tourette disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000023515 periodic limb movement disease Diseases 0.000 claims description 4
- YLFGRCPRRPAWIY-UHFFFAOYSA-N 3-(2-bromophenyl)-8-methyl-2-methylsulfanylquinazolin-4-one Chemical compound CSC1=NC2=C(C)C=CC=C2C(=O)N1C1=CC=CC=C1Br YLFGRCPRRPAWIY-UHFFFAOYSA-N 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- VTPBHYIYWZNATF-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-8-methyl-2-methylsulfanylquinazolin-4-one Chemical compound CSC1=NC2=C(C)C=CC=C2C(=O)N1C1=C(F)C=CC=C1F VTPBHYIYWZNATF-UHFFFAOYSA-N 0.000 claims description 2
- JHZBCNBXKITSRK-UHFFFAOYSA-N 3-(2-bromophenyl)-8-methyl-2-sulfanylidene-1h-quinazolin-4-one Chemical compound CC1=CC=CC(C2=O)=C1NC(=S)N2C1=CC=CC=C1Br JHZBCNBXKITSRK-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000001130 astrocyte Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 210000000274 microglia Anatomy 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 7
- 210000001218 blood-brain barrier Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000000324 neuroprotective effect Effects 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004002 dopaminergic cell Anatomy 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000003523 substantia nigra Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DJJOAJCVIYRELX-UHFFFAOYSA-N 3-phenyl-1h-quinazoline-2,4-dithione Chemical compound S=C1NC2=CC=CC=C2C(=S)N1C1=CC=CC=C1 DJJOAJCVIYRELX-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 239000000823 artificial membrane Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ZBUJNSDCOMAQRL-UHFFFAOYSA-N 2-methylsulfanyl-3-phenylquinazoline-4-thione Chemical compound CSC1=NC2=CC=CC=C2C(=S)N1C1=CC=CC=C1 ZBUJNSDCOMAQRL-UHFFFAOYSA-N 0.000 description 2
- FLTBNGICDDSHTN-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-1h-quinazoline-2,4-dithione Chemical compound FC1=CC=CC(F)=C1N1C(=S)C2=CC=CC=C2NC1=S FLTBNGICDDSHTN-UHFFFAOYSA-N 0.000 description 2
- PYTJFPPIDPMDLQ-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-2-sulfanylidene-1h-quinazolin-4-one Chemical compound FC1=CC=CC(F)=C1N1C(=O)C2=CC=CC=C2NC1=S PYTJFPPIDPMDLQ-UHFFFAOYSA-N 0.000 description 2
- CRGOYNYLYMPGKH-UHFFFAOYSA-N 3-phenyl-2-sulfanylidene-1h-quinazolin-4-one Chemical compound S=C1NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 CRGOYNYLYMPGKH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 150000002826 nitrites Chemical class 0.000 description 2
- 238000003178 parallel artificial membrane permeation assay Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 102000012438 2',3'-Cyclic-Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 description 1
- DWSMBORYMHSAEA-UHFFFAOYSA-N 3-[(4-amino-4-iminobutan-2-yl)diazenyl]butanimidamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)CC(C)N=NC(C)CC(N)=N DWSMBORYMHSAEA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IFIUFCJFLGCQPH-UHFFFAOYSA-N BRL-50481 Chemical compound CN(C)S(=O)(=O)C1=CC(N(=O)=O)=CC=C1C IFIUFCJFLGCQPH-UHFFFAOYSA-N 0.000 description 1
- 102000000131 Beta tubulin Human genes 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000004914 glial activation Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000007991 neuronal integrity Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000031337 regulation of inflammatory response Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Anvendelse af en forbindelse ifølge formel (I):
hvor: A, er en splejset carbocyklus eller heterocyklus eventuelt substitueret med 5, 6 eller 7 mættede eller umættede medlemmer, — kan være en dobbeltbinding; X og Y, er uafhængigt af hinanden valgt mellem gruppen bestående af hydrogen, alkyl, =0, =S, aryl, O-alkyl, O-aryl, S-alkyl eller -S-aryl; og R, R1, R2 og R3 er uafhængigt af hinanden valgt mellem gruppen bestående af hydrogen, halogen, alkyl, haloalkyl, aryl, cycloalkyl, (CH2)n-aryl, -OR3; - C(0)0R3, (CH2)n-C(0)0R3 eller -S(0)t-, hvor n er større end eller lig med O, og hvor t er 1 eller 2, eller et farmaceutisk acceptabelt salt, prodrug, solvat eller stereoisomer deraf, hvor prodruget er en ester af carboxylsyre, en aminosyreester, en phosphatester, en sulfona-testermetalsalt, en carbamat eller et amid afledt af forbindelsen ifølge formel (I), hvilken når administreret til et individ er i stand til direkte eller indirekte at tilvejebringe forbindelsen ifølge formel (I), til fremstilling af et lægemiddel til behandling af neurodegenerative og/eller neurologiske sygdomme, kendetegnet ved, at den neurodegenerative og/eller neurologiske sygdom er valgt blandt den følgende gruppe: Alzheimers sygdom, Parkinsons sygdom, amyotrofisk lateral sklerose, hjerneiskæmi, post-encephalitisk parkinson syndrom, dystoni, Tourettes syndrom, periodiske lemme-bevægelseslidelser, restless legs syndrome, forstyrrelse af aktivitet og opmærksomhed .
2. Anvendelse ifølge krav 1, hvor A er en carbocyklus med 6 medlemmer, fortrinsvis phenyl.
3. Anvendelse ifølge krav 1, kendetegnet ved, at forbindelsen ifølge formel (I) er en forbindelse ifølge formel (II):
hvor X og Y er uafhængigt af hinanden valgt mellem O eller S; og R og R1 er uafhængigt af hinanden valgt mellem gruppen bestående af hydrogen, ha-Awa#158371 logen, alkyl, haloalkyl, aryl, cycloalkyl, (CH2)n-aryl, heteroaryl,-OR3; -C(0)0R3, (CH2)n-C(0)0R3 eller -S(0)t-, hvor R3 er valgt mellem hydrogen, alkyl, aryl eller cycloalkyl, n er større end eller lig med 0 og t er 1 eller 2;
4. Anvendelse ifølge krav 3, hvor X er O og Y er S.
5. Anvendelse ifølge krav 3, hvor X er S og Y er S.
6. Anvendelse ifølge et hvilket som helst af krav 3 to 5, hvor R er valgt mellem H eller alkyl Ci-C5, fortrinsvis methyl.
7. Anvendelse ifølge krav 1, kendetegnet ved, at forbindelsen ifølge formel (I) er en forbindelse ifølge formel (III):
hvor: X er valgt mellem O eller S og Y er valgt mellem O-aryl eller S-alkyl; og R og R1 er uafhængigt af hinanden valgt mellem gruppen bestående af hydrogen, ha logen, alkyl, haloalkyl, aryl, cycloalkyl, (CH2)n-aryl, -0R3;-C(0)0R3, (CH2)n-C(0)0R3 eller -S(0)t-, hvor R3 er valgt mellem hydrogen, alkyl, aryl eller cycloalkyl, n er større end eller lig med 0 og t er 1 eller 2
8. Anvendelse ifølge krav 7, hvor X er O.
9. Anvendelse ifølge krav 7, hvor X er S.
10. Anvendelse ifølge et hvilket som helst af kravene 7 til 9, hvor Y er S-alkyl Ci-C6, fortrinsvis S-CH3.
11. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor R er valgt mellem H eller alkyl C1-C6, fortrinsvis methyl.
12. Anvendelse ifølge ethvert af de foregående krav, hvor R1 er phenyl substitueret eller ikke-substitueret.
13. Anvendelse ifølge de foregående krav, hvor R1 er phenyl substitueret med mindst én halogen valgt mellem Br eller F.
14. Anvendelse ifølge krav 1, kendetegnet ved, at forbindelsen ifølge formel (I) er en forbindelse valgt blandt den følgende gruppe: - 3-phenyl-4-oxo-2-thioxo-l,2,3,4-tetrahydroquinazolin, - 3-(2,6-difluorphenyl)-4-oxo-2-thioxo-l,2,3,4-tetrahydroquinazolin, - 3-(2-bromphenyl)-8-methyl-4-oxo-2-thioxo-l,2,3,4-tetrahydroquinazolin, - 3-(2,6-Difluorphenyl)-8-methyl-2-methylthio-4-oxo-3,4-dihydroquinazolin, - 3-(2-bromphenyl)-8-methyl-2-methylthio-4-oxo-3,4-dihydroquinazolin, - 3-Phenyl-2,4-dithioxo-l,2,3,4-tetrahydroquinazolin, og - 3-Phenyl-2-methylthio-4-thioxo-3,4-dihydroquinazolin - 3-(2,6-Difluorphenyl)-2,4-dithioxo-l,2,3,4-tetrahydroquinazolin. Awa#158371
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200930189A ES2353093B1 (es) | 2009-05-20 | 2009-05-20 | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
| PCT/ES2010/070338 WO2010133742A1 (es) | 2009-05-20 | 2010-05-20 | Uso de derivados de quinazolinas en enfermedades neurodegenerativas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2433637T3 true DK2433637T3 (da) | 2014-08-18 |
| DK2433637T5 DK2433637T5 (da) | 2015-08-31 |
Family
ID=42732572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10732398.2T DK2433637T5 (da) | 2009-05-20 | 2010-05-20 | Anvendelse af quinazolin derivater til neurodegenerative sygdomme |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9192610B2 (da) |
| EP (1) | EP2433637B9 (da) |
| JP (1) | JP5563068B2 (da) |
| AU (1) | AU2010251044B2 (da) |
| DK (1) | DK2433637T5 (da) |
| ES (2) | ES2353093B1 (da) |
| PL (1) | PL2433637T3 (da) |
| PT (1) | PT2433637E (da) |
| SI (1) | SI2433637T1 (da) |
| WO (1) | WO2010133742A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2118074T1 (sl) | 2007-02-01 | 2014-05-30 | Resverlogix Corp. | Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni |
| CN105859639A (zh) | 2009-03-18 | 2016-08-17 | 雷斯韦洛吉克斯公司 | 新的抗炎剂 |
| JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
| ES2544519B1 (es) | 2015-05-22 | 2016-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Quinazolinas S-sustituidas y sus aplicaciones terapéuticas para el tratamiento de enfermedades mediadas por PDE7 |
| JP6745824B2 (ja) | 2015-06-26 | 2020-08-26 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6740354B2 (ja) * | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
| WO2017069173A1 (ja) * | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3150878A1 (en) * | 2019-09-12 | 2021-03-18 | Jonathan Bentley | Inhibitors of sarm1 |
| WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07107056B2 (ja) * | 1987-01-30 | 1995-11-15 | 日清製粉株式会社 | ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤 |
| FR2828693B1 (fr) * | 2001-08-14 | 2004-06-18 | Exonhit Therapeutics Sa | Nouvelle cible moleculaire de la neurotoxicite |
| WO2005051974A2 (en) * | 2003-06-09 | 2005-06-09 | The Regents Of The University Of California | Novel molecules for regulating cell death |
| ES2308916B1 (es) * | 2007-03-22 | 2009-10-29 | Consejo Superior De Investigaciones Cientificas | Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones. |
| CN104758291B (zh) | 2007-03-27 | 2020-03-03 | 奥默罗斯公司 | 用于治疗运动障碍的pde7抑制剂的用途 |
| WO2008130619A2 (en) * | 2007-04-20 | 2008-10-30 | Trustees Of Boston College | A composition comprising an inhibitor of pde4 and/or pde7 |
-
2009
- 2009-05-20 ES ES200930189A patent/ES2353093B1/es not_active Expired - Fee Related
-
2010
- 2010-05-20 AU AU2010251044A patent/AU2010251044B2/en not_active Ceased
- 2010-05-20 PT PT107323982T patent/PT2433637E/pt unknown
- 2010-05-20 SI SI201030690T patent/SI2433637T1/sl unknown
- 2010-05-20 WO PCT/ES2010/070338 patent/WO2010133742A1/es active Application Filing
- 2010-05-20 PL PL10732398T patent/PL2433637T3/pl unknown
- 2010-05-20 US US13/321,046 patent/US9192610B2/en not_active Expired - Fee Related
- 2010-05-20 EP EP10732398.2A patent/EP2433637B9/en active Active
- 2010-05-20 ES ES10732398.2T patent/ES2498828T3/es active Active
- 2010-05-20 DK DK10732398.2T patent/DK2433637T5/da active
- 2010-05-20 JP JP2012511311A patent/JP5563068B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5563068B2 (ja) | 2014-07-30 |
| EP2433637B1 (en) | 2014-06-11 |
| US20120129877A1 (en) | 2012-05-24 |
| EP2433637B9 (en) | 2015-06-10 |
| ES2353093B1 (es) | 2012-01-03 |
| ES2498828T3 (es) | 2014-09-25 |
| SI2433637T1 (sl) | 2014-09-30 |
| PL2433637T3 (pl) | 2014-12-31 |
| EP2433637A1 (en) | 2012-03-28 |
| ES2353093A1 (es) | 2011-02-25 |
| AU2010251044B2 (en) | 2014-08-28 |
| AU2010251044A1 (en) | 2012-03-01 |
| US9192610B2 (en) | 2015-11-24 |
| PT2433637E (pt) | 2014-09-09 |
| DK2433637T5 (da) | 2015-08-31 |
| JP2012527434A (ja) | 2012-11-08 |
| WO2010133742A1 (es) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2433637T3 (da) | Anvendelse af quinazolin derivater til neurodegenerative sygedomme | |
| JP6876047B2 (ja) | ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物 | |
| EP2892518B1 (en) | Compositions for treating parkinson's disease | |
| CN111039939B (zh) | 用作蛋白质聚集抑制剂的杂芳基酰胺 | |
| CA3032609A1 (en) | Aldehyde trapping compounds and methods of use thereof | |
| US20040053989A1 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| EP3570940B1 (en) | Pridopidine for use in the treatment of fragile x syndrome | |
| US20240050409A1 (en) | Methods and Compositions for Treating Psychotic Disorders | |
| JP5649585B2 (ja) | ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物 | |
| ES2634204T3 (es) | Composición farmacéutica que comprende derivados de piridona | |
| Lorrio et al. | Novel multitarget ligand ITH33/IQM9. 21 provides neuroprotection in in vitro and in vivo models related to brain ischemia | |
| AU2013251079A1 (en) | Methods for treating Parkinson's disease | |
| CN107427517B (zh) | 用于痴呆症的预防及/或治疗的医药 | |
| Sharma et al. | Neuroprotective effect of peroxynitrite decomposition catalyst and poly (adenosine diphosphate—ribose) polymerase inhibitor alone and in combination in rats with focal ischemia | |
| JP2016536350A (ja) | キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法 | |
| CN113301893A (zh) | 神经性疾病的治疗 | |
| US10835532B2 (en) | Muscarinic agonists as cognitive enhancers | |
| US20220047550A1 (en) | Compounds and methods for the treatment of degenerative disorders | |
| IT201800005062A1 (it) | Modulatori dell’attività di segnale dell’indolamina 2,3-diossigenasi e loro impieghi terapeutici. | |
| US20210070730A1 (en) | H2s-based therapeutic agents for the treatment of neurodegenerative diseases | |
| US20210070799A1 (en) | Compounds for treating neurodegenerative disorders | |
| KR20050031499A (ko) | 뇌허혈성 질환의 예방 및 치료용 조성물 | |
| dos Santos | Role of Selective Kinases and Gdnf on Iron-mediated Alpha-synuclein Phosphorylation-relevance to Parkinson's Disease |